pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$PVLAPALVELLA THERAPEUTICS, INC.

$PVLA156.13-0.27%
Wayne, PA, USupdated 1d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 1: 1
1Phase 1
Phase 1
pitavastatin
Inherited Skin Disorders

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Aug 4, 2026
earnings
$PVLA156.13-0.27%
12d ago
PALVELLA THERAPEUTICS, INC. earnings
PALVELLA THERAPEUTICS, INC.
→
view all catalysts →

Active trials

  • phase2A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformationsactive not recruitingn=15
  • phase3SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformationsactive not recruitingn=51
  • phase2Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformationscompletedn=12
  • phase3VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenitacompletedn=36
  • phase3Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenitacompletedn=73
  • phase3A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenitacompletedn=87
  • phase2CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndromecompletedn=73

Insider activity

source: SEC Form 4

open-market buys + sells

  • Apr 15, 26SELLGoin Kathleen· Chief Operating Officer1,500 sh @ $127.13−$191K↗
  • Apr 15, 26SELLGoin Kathleen· Chief Operating Officer1,502 sh @ $125.96−$189K↗
  • Apr 15, 26SELLGoin Kathleen· Chief Operating Officer639 sh @ $129.17−$83K↗
  • Apr 15, 26SELLGoin Kathleen· Chief Operating Officer561 sh @ $128.23−$72K↗
  • Apr 15, 26SELLGoin Kathleen· Chief Operating Officer100 sh @ $130.33−$13K↗
  • Mar 30, 26BUYJENKINS GEORGE M· 445 sh @ $112.30$50K↗
  • Mar 18, 26SELLGoin Kathleen· Chief Operating Officer2,268 sh @ $117.56−$267K↗
  • Mar 18, 26SELLGoin Kathleen· Chief Operating Officer1,730 sh @ $118.37−$205K↗
  • Mar 18, 26SELLGoin Kathleen· Chief Operating Officer304 sh @ $119.08−$36K↗
  • Feb 27, 26BUYJENKINS GEORGE M· 4,000 sh @ $125.00$500K↗
  • Feb 27, 26BUYHERON ELAINE J· 2,400 sh @ $125.00$300K↗
  • Feb 18, 26SELLGoin Kathleen· Chief Operating Officer3,026 sh @ $79.16−$240K↗
  • Feb 18, 26SELLGoin Kathleen· Chief Operating Officer1,276 sh @ $79.97−$102K↗
routine RSU / option mechanics (6)
  • Apr 15, 26option exerciseGoin Kathleen · Chief Operating Officer2,148 sh
  • Apr 15, 26option exerciseGoin Kathleen · Chief Operating Officer2,154 sh
  • Apr 15, 26option exerciseGoin Kathleen · Chief Operating Officer2,154 sh
  • Apr 15, 26option exerciseGoin Kathleen · Chief Operating Officer2,148 sh
  • Apr 13, 26grantDoux John · 6,000 sh
  • Mar 18, 26option exerciseGoin Kathleen · Chief Operating Officer2,148 sh
🐶 Hiring Signal
No open roles indexed yet — view PALVELLA THERAPEUTICS, INC. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$PVLA
SEC CIK
0001583648
country
US
source
sec_tickers
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 2m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?